Trial Profile
A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs CPCB-RPE1 (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; First in man
- Sponsors Regenerative Patch Technologies
- 04 Feb 2022 Results presented in a Regenerative Media Release.
- 04 Feb 2022 According to a Regenerative Patch Technologies media release, data published online in Stem Cell Reports.
- 28 Jun 2021 Results published in the Regenerative Patch Technologies Media Release.